Document Detail


Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events.
MedLine Citation:
PMID:  19702845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Gastric cancer remains one of the most common cancers worldwide. A strong association exists between Helicobacter pylori infection and the risk of developing noncardia gastric cancer. H. pylori eradication by antibiotic treatment is regarded as a primary chemoprevention strategy to reduce gastric cancer incidence. AIM: To analyze the efficacy of H. pylori eradication in preventing gastric cancer in human and animal models, and to discuss whether biochemical, genetic, and epigenetic changes associated with H. pylori infection are reversible after curing the infection. RESULTS: Several intervention trials have indicated that in some patients, H. pylori eradication leads to regression and prevents the progression of precancerous lesions. The eradication therapy reduces gastric cancer incidence in patients without any precancerous lesions at the baseline and is most effective before the development of atrophic gastritis. A few recent intervention studies in Japan have demonstrated significant prophylactic effects of eradication therapy on the development of gastric cancer, suggesting the use of eradication therapy in high-risk populations as a gastric cancer reduction strategy. However, gastric cancer may still develop despite successful eradication therapy. Studies in animal models have confirmed the use of eradication therapy at an early point of infection to prevent gastric cancer development. CONCLUSION: H. pylori eradication may not completely abolish the risk of gastric cancer. However, eradication therapy may be used in high-risk populations to reduce gastric cancer incidence. It can reverse many biochemical, genetic, and epigenetic changes that H. pylori infection induces in the stomach.
Authors:
Shahjahan Kabir
Related Documents :
12376025 - Hematogenous infections due to candida parapsilosis: changing trends in fungemic patien...
21091995 - Autofluorescence imaging for predicting development of metachronous gastric cancer afte...
18986545 - A prospective study of helicobacter pylori in relation to the risk for pancreatic cancer.
9659265 - Caga seropositivity associated with development of gastric cancer in a japanese populat...
22003275 - Synthesis and in vitro antiproliferative activity of novel (4-chloro- and 4-acyloxy-2-b...
20696685 - Which staging system to use for gynaecological cancers: a survey with recommendations f...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Helicobacter     Volume:  14     ISSN:  1523-5378     ISO Abbreviation:  Helicobacter     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-08-25     Completed Date:  2009-10-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9605411     Medline TA:  Helicobacter     Country:  United States    
Other Details:
Languages:  eng     Pagination:  159-71     Citation Subset:  IM    
Affiliation:
Academic Research and Information Management, Uppsala, Sweden. acarim99@yahoo.co.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Bacterial Agents / therapeutic use*
Clinical Trials as Topic
Helicobacter Infections / complications*,  drug therapy*
Helicobacter pylori / drug effects*
Humans
Incidence
Japan
Models, Animal
Stomach Neoplasms / epidemiology*,  prevention & control
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A genetic background with low mutational robustness is associated with increased adaptability to a n...
Next Document:  Immunoblot analysis as an alternative method to diagnose enterohepatic Helicobacter infections.